Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada

by Zacks Equity Research

Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.

    Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

    by Zacks Equity Research

    Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

      Puma Soaring After Neratinib FDA Panel Win, Time to Buy?

      by Zacks Equity Research

      Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.

        Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data

        by Zacks Equity Research

        Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study

          Aerie's Ophthalmic Candidate Positive in Registration Trial

          by Zacks Equity Research

          Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.

            Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

            by Zacks Equity Research

            Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).

              Regeneron Presents Positive Phase II Data on HoFH Candidate

              by Zacks Equity Research

              Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.

                Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session

                by Zacks Equity Research

                Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day.

                  Horizon (HZNP) Sells European Rights for Procysbi & Quinsair

                  by Zacks Equity Research

                  Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.

                    Novartis (NVS) Reports Positive Data on Ultibro Breezhaler

                    by Zacks Equity Research

                    Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.

                      Achaogen's Plazomicin Gets Breakthrough Therapy Designation

                      by Zacks Equity Research

                      Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.

                        5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio

                        by Zacks Equity Research

                        Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs

                          Theravance/Mylan Presents Phase III Data on COPD Candidate

                          by Zacks Equity Research

                          Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key pipeline candidate, revefenacin (TD-4208).

                            Ultragenyx Receives Priority Review for rhGUS from FDA

                            by Zacks Equity Research

                            The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.

                              BioLineRx Makes Regulatory Submission for Trial of BL-8040

                              by Zacks Equity Research

                              BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

                                Merck Presents Phase II Data on Chronic Cough Candidate

                                by Zacks Equity Research

                                Merck (MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference.

                                  Roche's Arthritis Drug Gets FDA Nod for Label Expansion

                                  by Zacks Equity Research

                                  Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).

                                    Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint

                                    by Zacks Equity Research

                                    Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.

                                      Catalyst Pharmaceuticals Focuses on Development of Firdapse

                                      by Zacks Equity Research

                                      We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.

                                        Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study

                                        by Zacks Equity Research

                                        Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.

                                          AstraZeneca Sells Marketing Rights to Seloken in Europe

                                          by Zacks Equity Research

                                          AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.

                                            Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

                                            by Zacks Equity Research

                                            Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

                                              Amgen Evenity Approval Derailed on Cardiovascular Side Effect

                                              by Zacks Equity Research

                                              A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.

                                                Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose

                                                by Zacks Equity Research

                                                Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.

                                                  Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

                                                  by Zacks Equity Research

                                                  Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.